Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
Close
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
Close
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global Clinical Research Organizations in 2021| Medicilon Pharmacokinetic Services for First-in-Class Ubiquitination Inhibitor Development| ADC, precision and deep cultivation for targeted drug delivery
Jan 05,2023
The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs
The Ames test is short-term in vitro test method for preliminary screening of the mutagenicity of chemical substances by using the properties of the reverse mutation of the histidine auxotrophic mutant strain of Salmonella typhimurium.
More
The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs
Dec 27,2022
What is Meant by Target Validation and How is Target Validation Done?
Target validation refers to the accumulation of scientific evidence that a target (usually a protein) is modulated (usually inhibited) for therapeutic use.
More
What is Meant by Target Validation and How is Target Validation Done?
Dec 26,2022
"China's Pharmaceutical CDMO Industry Map in 2021" is Coming-Echelon Ranking and Distribution
As an essential part of the new drug research and development industry, the company provides services throughout the entire life cycle of the drug, from preclinical research to clinical phase I and before the drug patent expires.
More
"China's Pharmaceutical CDMO Industry Map in 2021" is Coming-Echelon Ranking and Distribution
Dec 26,2022
CDMO Development Enters the Fast Lane
The primary source of CDMO demand is the outsourcing part of process development and experimental drug production of large and small pharmaceutical companies.
More
CDMO Development Enters the Fast Lane
Dec 23,2022
Global CDMO Catalent
Catalent, headquartered in New Jersey, has nearly 90 years of experience developing new drugs, with sales of 4 billion US dollars in 2021. The multifunctional pharmaceutical manufacturing platform in more than 50 locations worldwide provides more than 70 billion doses and 7000 million doses to more than 1,000 customers annually.
More
Global CDMO Catalent
Dec 02,2022
What is CRO,CMO,CDMO
Contract Research Organization referred to as CRO, mainly provides drug discovery, preclinical research, clinical trials, and other new drug R&D contract research services for multinational pharmaceutical companies and pharmaceutical companies. Biomedical R&D outsourcing has gradually become an indispensable link in the pharmaceutical industry chain and plays a vital role in the industrial structure.
More
What is CRO,CMO,CDMO
Oct 12,2022
Toxicity of ADC drugs
On February 3rd, Johnson & Johnson announced that it had reached a cooperation agreement with Mersana Therapeutics to jointly develop three new generation ADC drugs.
More
Toxicity of ADC drugs
Oct 11,2022
Present Situation, Challenge, Opportunity and Future of ADC
At present, a variety of antibody-coupled drugs (ADC) have been approved for the treatment of solid tumors, and have been rapidly extended to indications of multiple tumor types. For example, anti-HER2 ADC, anti-Trop-2 ADC, anti-nectin-4 ADC, etc.
More
Present Situation, Challenge, Opportunity and Future of ADC
Sep 30,2022
Medicilon Pharmacokinetic Services for First-in-Class Ubiquitination Inhibitor Development
TAK-243 was found to have significant antitumor activity. Among other things, researchers conducted in vivo efficacy experiments using the HCC-70 model through Medicilon. The results revealed a tumor growth inhibition (TGI) rate of 91%.
More
Medicilon Pharmacokinetic Services for First-in-Class Ubiquitination Inhibitor Development
Sep 29,2022
Complete Process DMPK Service Helps PROTAC Drug Development
Through the principle of PROTAC technology, medicilon, combined with R&D cases, uses the perfect in vitro ADME and in vivo PK testing platform to establish a screening and IND evaluation system on PROTAC drugs based on small molecule compound research, focusing on drug solubility, permeability, metabolic stability, metabolite identification and in vivo PK studies, etc., to help customers quickly advance the development of PROTAC drugs.
More
Complete Process DMPK Service Helps PROTAC Drug Development
Stock Code
688202

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->